The U.S. Food and Drug Administration (FDA) has announced pre-market approval for Magtrace, the first non-radioactive, dual-tracer for lymphatic mapping in patients with breast cancer undergoing a mastectomy. Magtrace is a liquid marker designed to...
Original Article: FDA approves non-radioactive, dual-tracer for sentinel lymph node biopsy